Can Retatrutide beat Ozempic? New weight-loss drug shows surprising trial results

A new experimental medicine for weight loss is creating major discussion among doctors and health experts. The drug, called Retatrutide, has shown strong results in clinical trials, with some people losing a large amount of weight over time.

The medicine is being developed by Eli Lilly, the same company known for diabetes and obesity treatments. According to trial results released recently, people taking Retatrutide lost a large percentage of body weight, leading some doctors to compare its effects with weight-loss surgery.

Even though the medicine is not yet approved for public use, experts say the early results are impressive and could change how obesity treatment works in the future.

Obesity is a major health problem around the world. It increases the risk of diabetes, heart disease, high blood pressure, sleep problems and joint pain. Many people struggle to lose weight even after trying exercise, dieting and lifestyle changes.

Because of this, medicines that support long-term weight loss are getting more attention.

Retatrutide is now being discussed because of how much weight some participants lost during testing.

According to the company, people in late-stage clinical trials lost around 28 percent of their body weight after about 80 weeks of treatment.

In simple terms, this means someone weighing 250 pounds could lose nearly 70 pounds on average.

Some participants reportedly lost even more weight during extended treatment periods.

The company said people with severe obesity who stayed on the medicine for nearly two years lost around 85 pounds on average, equal to nearly 30 percent of their body weight.

Doctors say such numbers are unusually high for a medication.

Many experts compare this level of weight loss to bariatric surgery, a medical operation done to help people with serious obesity lose weight.

Bariatric surgery changes the digestive system to reduce food intake and improve health.

Usually, surgery produces major weight loss, while medicines give smaller results.

However, Retatrutide’s trial numbers are making experts reconsider how powerful medicines can become.

Some doctors believe this medicine may help people who need major weight reduction but cannot undergo surgery.

Researchers also found that the medicine may improve several health markers linked to obesity.

Participants reportedly showed improvements in waist size, blood pressure and cholesterol levels.

This is important because obesity often affects the heart and blood vessels.

Reducing these risk factors may improve long-term health and lower the risk of disease.

How Retatrutide works differently

Many people compare Retatrutide with popular medicines such as Ozempic, Wegovy and Zepbound.

These medicines have become widely known for helping people lose weight and manage diabetes.

Ozempic and Wegovy contain semaglutide and work by copying a hormone called GLP-1.

This hormone helps control hunger and blood sugar.

People taking Wegovy often lose around 15 percent of their body weight on average.

Another medicine, Zepbound, works differently.

It targets two hormones called GLP-1 and GIP.

Because it works on more than one system, it generally helps people lose more weight, around 21 percent on average.

Retatrutide goes one step further.

Experts describe it as a “triple-agonist” because it works on three hormones instead of one or two.

These hormones include GLP-1, GIP and glucagon.

The medicine affects hunger, calorie burning and fat metabolism.

Doctors believe this combination may explain why participants lost more weight during trials.

In simple language, the medicine may help people eat less, feel full faster and burn energy differently.

Some experts say targeting more body systems may produce stronger weight-loss effects.

At present, there are no direct studies comparing Retatrutide with Ozempic or other medicines in head-to-head testing.

This means researchers cannot officially say it is better yet.

Still, doctors say the early numbers are attracting attention because of how strong the results appear.

Some experts believe Retatrutide may help people who did not respond well to older obesity medicines.

Others think it may help people who stopped losing weight after reaching a plateau with current treatments.

A weight-loss plateau happens when progress slows or stops after initial success.

In such cases, doctors may look for stronger treatment options.

ALSO READ: Why overthinking gets worse after midnight, according to experts

ALSO READ: Vaping, smoking and chewing tobacco are harming more than just the lungs, doctors warn

Side effects and who may benefit

Like many medicines, Retatrutide also comes with possible side effects.

Doctors say most problems reported during testing were similar to those seen in other weight-loss medicines.

Many people experienced stomach-related problems.

Common side effects included nausea, vomiting, constipation and diarrhoea.

These problems are often seen in medicines affecting appetite and digestion.

Some participants also reported infections such as upper respiratory illness or urinary tract infections.

A few people experienced unusual skin sensations.

Not everyone tolerated the medicine well.

According to trial data, around 11 percent of participants stopped treatment because of side effects.

This number was higher than among people receiving placebo treatment.

Experts say this highlights the importance of careful medical supervision.

Doctors also stress that these medicines are not for everyone.

Some people may not need dramatic weight loss.

For someone who is slightly overweight, very strong medication may not be necessary.

Experts believe Retatrutide may be most useful for people with severe obesity, especially those with a body mass index, or BMI, above 35.

These patients often face serious health risks linked to weight and may benefit from stronger medical support.

Doctors also say medicines alone are not enough.

Healthy eating, exercise, proper sleep and long-term lifestyle changes still matter.

Even with medication, habits such as balanced nutrition and regular physical activity remain important.

Another important point is that Retatrutide has not yet received approval from health authorities.

The medicine still needs review before becoming available to the public.

Researchers will continue studying safety, side effects and long-term benefits.

Even so, experts believe the trial results mark an important moment in obesity treatment.

For years, weight-loss medicines showed only moderate effects.

Now, stronger treatments may offer new hope to people struggling with severe obesity.

While more research is still needed, Retatrutide is already becoming one of the most talked-about medicines in the field of weight management.